UltraNuclease Residual Detection ELISA: Sensitive Quantification for Bioprocess Quality Control
How to Accurately Detect UltraNuclease Residual Risk in Biologics
UltraNuclease is a highly active, broad-spectrum nucleic acid degrading enzyme widely used in biologics manufacturing. It removes residual host cell nucleic acids and lowers the immunogenicity risk of the final product. Because the enzyme itself is an exogenous protein, reliable residual detection has become a critical part of biologics safety evaluation.
Does Widespread Use of UltraNuclease Always Create a Residual Safety Risk?
UltraNuclease efficiently cleaves both DNA and RNA, which markedly improves product purity. However, as an exogenous protein, any residue carried into the final product may trigger immune responses or other unpredictable biological effects. Establishing a reliable, sensitive, and specific detection method is therefore essential.
The challenge is compounded by process variability. Addition amounts, incubation times, and the efficiency of removal steps all differ across manufacturing stages. This variability raises the complexity of residue control and places higher demands on assay performance.
What Is the Design Principle of UltraNuclease Residual Detection Kits?
Most UltraNuclease residual detection kits on the market use a double-antibody sandwich enzyme-linked immunosorbent assay. A monoclonal antibody that specifically recognizes UltraNuclease is coated onto the microplate surface.
After the sample is added, UltraNuclease binds to the immobilized antibody. An enzyme-labeled secondary antibody is then introduced, forming a solid-phase antibody–antigen–enzyme-labeled antibody complex. Adding a chromogenic substrate and measuring absorbance enables quantitative analysis of UltraNuclease content.
This workflow depends on a highly specific antigen–antibody reaction. It effectively excludes interference from other proteins in the biologics matrix, which safeguards assay accuracy. Some improved kits also introduce a biotin–streptavidin signal amplification system. That addition raises sensitivity further without changing the core detection principle.
Can the Method Meet Regulatory Requirements for Sensitivity and Specificity?
Regulators set strict residue limits for process-related impurities in biologics. As an exogenous additive, UltraNuclease usually must be controlled at the nanogram per milliliter level or lower in the final product. Experimental validation shows that high-quality residual detection kits reach a limit of detection of 0.1–1.0 ng/mL. The limit of quantification remains stable within 1.0–5.0 ng/mL. These figures fully satisfy current pharmacopeial and industry guidance requirements for residual impurities.
Specificity is equally important. The kit shows no significant cross-reactivity with common host cell proteins, cytokines, or other nucleases. It therefore identifies the target residue accurately despite complex sample backgrounds. The standard curve linear range typically covers 0.1–100 ng/mL, which accommodates different residue levels. This range supports both process development and final product release testing.
Which Control Points Matter in Sample Preparation and Operation?
Sample pretreatment is vital for results that truly reflect UltraNuclease residue levels. First, select a dilution buffer that suits the dosage form and matrix of the specific biologics. Avoid drastic shifts in pH or ionic strength, which can alter enzyme protein conformation and affect epitope recognition.
Second, for samples with high protein content or surfactants, dilute in advance or use a dedicated sample diluent to reduce matrix effects. During operation, control incubation temperature and time strictly, typically using room temperature or 37°C constant-temperature shaking incubation. Washing steps must thoroughly remove unbound protein while avoiding excessive washing that disrupts the formed antigen–antibody complex.
Fit the standard curve with a four-parameter logistic regression model to ensure quantitative accuracy. In addition, set negative, positive, and blank controls in every run to monitor plate-to-plate variation and systematic error.
What Are the Limitations in Practical Application, and How Should They Be Addressed?
Although these kits perform well in most scenarios, limitations remain. High concentrations of lipids or non-ionic surfactants may interfere with antigen–antibody binding and push recovery outside the ideal range. In addition, degraded UltraNuclease fragments that retain partial epitopes may cause false-positive estimation of residue levels.
For these problems, run adequate spike-and-recovery experiments and dilution linearity validation during method establishment. That work identifies the optimal sample treatment for a given product. Parallel analysis by high-performance liquid chromatography or mass spectrometry can provide cross-validation for the ELISA result, further improving the reliability of the residue risk assessment. For samples with unsatisfactory recovery, consider changing the dilution buffer composition or adding an affinity purification pretreatment step.
Conclusion and Outlook
In summary, UltraNuclease residual detection kits based on the double-antibody sandwich ELISA principle perform well in sensitivity, specificity, and operational convenience. They effectively support biologics process validation and quality control.
Because UltraNuclease is added at different stages and removed by different unit operations, residual levels can vary widely between processes and between batches. A robust assay must therefore cover a broad dynamic range without diluting samples below the limit of quantification. It must also tolerate the diverse matrices found in monoclonal antibody, vaccine, and cell therapy products. Method validation should confirm accuracy, precision, dilution linearity, and robustness across these matrices before the assay is used for release testing.
As detection technology advances, faster and more automated chemiluminescence or time-resolved fluorescence immunoassays are expected to replace traditional colorimetric methods. These platforms should improve both throughput and data reproducibility while reducing hands-on time. Ultimately, pairing a well-characterized kit with a validated method gives process scientists and quality teams the confidence to track UltraNuclease clearance accurately.
Related Products
The UltraNuclease OneStep ELISA Kit is a competitive option for laboratories that need sensitive, specific residual detection. The kit uses a one-step double-antibody sandwich ELISA format developed specifically for UltraNuclease. It suits biologics process monitoring, cell therapy product quality control, vaccine production residue testing, and nucleic acid contamination assessment in research laboratories.
| Product Name | Catalog No. |
|---|---|
| UltraNuclease OneStep ELISA Kit | S0C3161 |
Key Features
| Key Advantage | Detailed Parameter / Function |
|---|---|
| High sensitivity and specificity | Validated through strict paired antibody screening and optimization; specifically detects UltraNuclease protein with no significant cross-reactivity against common host cell proteins or process residues. Sensitivity reaches the sub-ng/mL level, meeting stringent quality control requirements for residual nucleases in biopharmaceutical manufacturing. |
| One-step convenient operation | Uses pre-coated plates and an optimized reagent system to simplify the multi-step ELISA workflow. Sample and detection antibody are added simultaneously for incubation, shortening the entire workflow to within 2 hours. Simplified handling reduces human error and improves efficiency. |
| Strict quality control for lot-to-lot consistency | Every lot is validated for linear range, sensitivity, precision, and recovery. Intra-plate and inter-lot variation is kept within a very narrow range, providing stable and reliable data for multi-lot release and long-term process monitoring. |
| Complete kit configuration | Includes ELISA plates pre-coated with capture antibody, biotinylated detection antibody, HRP conjugate reagent, chromogenic substrate, stop solution, standards, and diluent. No additional auxiliary reagents are required, so the kit is ready to use out of the box. |
ANT BIO PTE. LTD. has built a mature rabbit immunization and single B cell antibody development platform. It covers antigen design and immunization strategy optimization, high-throughput single B cell sorting, antibody gene cloning, recombinant expression, and multi-application validation. The platform delivers systematic antibody customization solutions for different application scenarios. To learn more about the UltraNuclease OneStep ELISA Kit or to request a sample test, please contact us.
ANT BIO PTE. LTD. – Empowering Scientific Breakthroughs
At ANTBIO, we are committed to advancing life science research by delivering high-quality recombinant proteins, antibodies, and assay kits. Our products are developed under rigorous quality control systems and are intended for basic research use only. We believe that reliable reagents accelerate discovery, and we continuously invest in platform development to support the global research community.
Disclaimer
This article was created with partial assistance from artificial intelligence. If any content involves copyright or intellectual property issues, please notify us, and we will verify and remove it promptly. The information provided is for basic research reference only and does not constitute clinical or diagnostic guidance.
